Widely used drugs on US imports list from Europe
[1/2] A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, in New York City, U.S., December 11, 2023 (left) and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly, at Rock Canyon Pharmacy in Provo, Utah, U.S., March 29,... Purchase Licensing Rights, opens new tab Read more
March 18 (Reuters) - Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
The following is a list of major prescription drugs whose ingredients or components are imported into the United States from the European Union, based on U.S. Food and Drug Administration import data from 2023 and 2024.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Company Brand Name (chemical name) Used to Treat Country of Import Company Comments
AbbVie (ABBV.N) Rinvoq (upadacitinib) rheumatoid arthritis Germany, Ireland Abbvie declined to comment on specific production or import sites for its drugs. The company said it "maintains a robust, diversified and redundant manufacturing network with geographic balance and multiple supply sites"
Norvir (ritonavir) HIV Germany
Humira (adalimumab) rheumatoid arthritis, psoriatic arthiritis, others Germany
Amgen (AMGN.O) Blincyto (blinatumomab) A type of acute lymphoblastic leukemia Netherlands
Prolia/Xgeva (denosumab) osteoporosis, preventing fractures from cancer in bones Netherlands
Bavarian Nordic A/S (BAVA.CO) Jynneos smallpox vaccine, also used for mpox Denmark Bavarian Nordic said it manufactures all its bulk vaccine/bulk drug substance for Jynneos in Denmark, and the fill and finish is done either at its own site in Denmark or in the U.S., depending on the markets served.
Bristol Myers Squibb (BMY.N) Eliquis (apixaban) Blood thinner/clot preventer Ireland
Opdivo (nivolumab) cancer immunotherapy Ireland
Eli Lilly (LLY.N) Mounjaro, Zepbound (tirzepatide) type 2 diabetes, obesity Germany, Netherlands A Lilly spokesperson said the company prefers to source materials internally, as evidenced by its most recent manufacturing announcements. It does not disclose details of in-house vs external manufacturing
Johnson & Johnson (JNJ.N) Stelara (ustekinumab) inflammatory bowel disease, psoriatic arthritis, other autoimmune conditions Ireland, Netherlands
Invega/Invega Sustenna (paliperidone) schizophrenia Ireland
Merck & Co (MRK.N) ritonavir antiviral Netherlands
Keytruda (pembrolizumab) cancer immunotherapy Netherlands, Ireland
Gardasil HPV vaccine for cancer prevention Ireland
Novavax (NVAX.O) Nuvaxovid COVID-19 vaccine Germany Novavax said its vaccine is manufactured by The Serum Institute in India.
Novo Nordisk (NOVOb.CO) Ozempic (semaglutide ) type 2 diabetes, Ireland, Germany, Denmark Novo said in a statement that it manufactures the active ingredients for its obesity and diabetes drugs in Denmark and United States only
Wegovy (semaglutide) obesity Ireland, Germany
Pfizer (PFE.N) Prevnar family pneumococcal vaccines for pneumonia prevention Ireland
Penbraya meningococcal meningitis vaccine Ireland
Comirnaty COVID-19 vaccine Ireland, Germany
Eliquis (apixaban) blood thinner/clot preventer Netherlands
Regeneron (REGN.O) Eylea (aflibercept ) Wet age-related macular degeneration, other eye conditions Ireland Regeneron has manufacturing facilities in both the U.S. and Ireland and is currently expanding its campus in New York.
Roche (ROG.S) Avastin (bevacizumab) metastatic colorectal cancer, diabetic eye disease and other eye disorders Germany Roche declined to comment on which drug is produced where, and for which market. It said that a majority of its products cross different countries/continents across the development and supply chain.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
30 minutes ago
- Times
Mounjaro UK price rise will trigger obesity relapse, say experts
The upcoming Mounjaro price hike could cause people to pile weight back on and 'cycle in and out of obesity', experts have warned. The weight-loss jab, which is bought privately by 1.5 million people in the UK, will more than double in price next month — forcing patients off the drug if they can no longer afford it. Its manufacturer, Eli Lilly, is increasing the list price for the maximum 15mg dose from £122 to £330 for a monthly pen, while the 5mg dose is rising from £92 to £180. Pharmacies have warned that patients are in 'immense distress', with demand soaring as they stock up on Mounjaro before the price increase takes effect on September 1. Professor Tim Spector, a nutrition expert at King's College London, warned that the sudden increase in price had exposed the flaws of relying on weight-loss jabs to lose weight. He said: 'The price rise of the GLP-1 drugs comes at a tricky time for the million-plus Britons that have started taking the drugs. Any losses in weight they will have achieved will be reversed in just a few weeks, as their appetite kicks back in. 'People are being prompted to use these private networks of GLP-1 drugs without any real supervision, and, crucially, without any nutritional support.' Spector, co-founder of the Zoe nutrition app, said that people who were taking weight-loss jabs should instead have been 're-educated about food and good eating habits long term'. He added: 'It's a huge wasted opportunity that's going to get worse as the price for the consumer goes up, and therefore people are unlikely to stay on this long term. We're just going to be back to good old short-term diets, which will cycle people in and out of obesity.' The price hike is taking place after President Trump demanded that pharmaceutical firms lower prices for American patients and stop other countries 'freeloading' off US firms. Pharmacies said they were experiencing record demand and were helping people to switch from Mounjaro to Wegovy, a similar GLP-1 drug known as Ozempic when used for diabetes, as it is cheaper, although not thought to be as effective. • Jon Yeomans: Mounjaro is a taste of the battle to come over drug prices James O'Loan, the chief executive of the online pharmacy Chemist4U, said: 'The distressing news that prices are set to rise by up to 170 per cent with just two weeks' notice, in response to another aggressive initiative from Trump, is very troubling. It's caused immense distress to hundreds of thousands of UK patients on a weight loss journey, who worry all their hard-earned progress could be snatched away from them.' Asda Online Doctor said: 'Following the announcement of steep price increases by the manufacturer Eli Lilly starting in September, we have seen an instant 350 per cent increase in demand. We are making all efforts to enable our existing patients to continue treatment and are actively prioritising them. 'However, this will be a difficult situation for many of our patients with affordability being a key aspect in the access and/or continuation of these services. Therefore we deeply regret this decision from Eli Lilly to increase prices, which will affect many patients. We remain committed to providing an excellent service to our patients at a fair price.' • Mounjaro transformed me — but it had a huge effect on my family's life Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, representing thousands of community pharmacies, said: 'Our members up and down the country have been dealing with worried patients, many of whom are enquiring about stocking up before the price increase hits. 'There is a very real danger that the higher prices will see patients desperate for cheaper products turn to the, often unregulated, online market.' Sandeep Dhami, a superintendent pharmacist at MW Phillips Chemists in the West Midlands, added: 'Patients on their weight-loss journeys are coming into pharmacies like mine angry and upset at the news of the price hike. Those on the highest doses, who will face the highest price hike are particularly concerned.'
STV News
4 hours ago
- STV News
Weight loss jabs for cats and dogs: Are pets next in line for Ozempic?
Pets could soon be following their owners in using revolutionary weight-loss drugs such as Mounjaro and Ozempic. Scientists are developing and testing veterinary versions of the GLP-1 medicines for use on cats and dogs. As part of a partnership between drug companies Okava and Vivani, early-stage clinical trials in cats found that small doses successfully reduced the animals' calorie intake and body weight. Plans have been announced for an implant that reproduces the effect in dogs – with the aim of bringing it to the market as soon as 2028. It comes after a recent study estimated that around 60% of dogs and 39-52% of cats in the UK are deemed overweight. Vets have warned against the weight loss drugs – suggesting that owners would be better off avoiding obesity in their pets through more old-fashioned methods, such as exercise and restrictive diets. Caroline Allen, the RSPCA's chief veterinary officer, said: 'A healthy diet and exercise are the best ways to keep our pets happy and well, but we understand that owners can sometimes struggle to manage their pets' weight. 'There is currently little information about proposed weight-loss implants or vaccinations for animals, and owners shouldn't rely on them becoming available. 'Before resorting to these sorts of interventions, owners should seek help from their vet about how to reduce their pet's weight with a good diet and providing lots of opportunities to exercise and play in ways that their pet will enjoy.' Mary Swift via Adobe Stock Plans have been announced for an implant that reproduces the effect in dogs – with the aim of bringing it to the market as soon as 2028. The active ingredient in Mounjaro is tirzepatide, and in Ozempic, it is semaglutide. Both work by mimicking a hormone produced in the body called GLP-1, a substance released in the gut when people consume food. This hormone regulates blood sugar and appetite, slowing the rate at which food is emptied from the stomach, ultimately leading people to feel fuller for longer and therefore less hungry. While the human versions are administered by injections once a week – the pet drugs would be delivered via implants. A trial of the drug Exenatide last year fitted five cats with an experimental subcutaneous implant, known as OKV-119, which released the weight-loss chemical into the blood for 84 days. Analysis found four of five cats had a reduction in body mass of at least 5%. Okava, a San Francisco-based biopharma company that specialises in pet health and is running trials desgined to mimic the effects of Ozempic, said using the drugs can help avoid 'disrupting the human-animal bond'. 'Caloric restriction, or fasting, is one of the most well-established interventions for extending the lifespan and improving metabolic health in dogs,' said Okava CEO Michael Klotsman. 'But it is also one of the hardest to maintain. 'OKV-119 mimics many of the physiological effects of fasting—improved insulin sensitivity, reduced fat mass and more efficient energy metabolism—without requiring significant changes in feeding routines or disrupting the human-animal bond that often centres around food.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
The Sun
4 hours ago
- The Sun
I lost 12st with fat jabs and reversed high blood pressure and joint pain – ex-boyfriends are crawling back
A WOMAN who lost 12 stone on Mounjaro jabs has overhauled her health and says her biological clock hsa reduced by 16 years. Susan Forgie's transformation has brought about an unexpected side effect - as the 75-year-old says her exes have come crawling back. 7 7 Susan had been yo-yo dieting since her teenage years. Doctors became concerned when she reached 23 stone, as she grappled with a number of health issues including 'sky-high' blood pressure. She was referred to an obesity clinic, which recommended she try weight loss medication to help slim down. The 75-year-old hasn't looked back since – overhauling her health and reducing her metabolic age to that of a 59-year-old. 'A couple of men I dated prior to losing weight have commented that they should never have let me go and shouldn't we try again,' Susan, from Oswestry, Shropshire, said. 'Someone at the gym asked me to go for a drink with him, and someone else I have known for years says he can't stop thinking about me. 'I get looks I never used to have.' Despite the attention, Susan is happily with her partner Tim, 74, whom she met after she shed six stone. Having seen her success, he started taking Mounjaro himself and lost over two stone. Susan added: 'My friends and family have been stunned by my transformation, too. 'I've never been the average pensioner, but, because of my size, I've never been able to follow fashion. Weight Loss Jabs - Pros vs Cons 'I'm no longer restricted by wearing only what clothes are in my size – I wear a lot more colour now. 'I've replaced all the clothes in my wardrobe, having gone from a size 22/24 to a 12/14. 'I was never able to wear fashionable clothes like over-the-knee long leather boots – but I can now.' 7 7 The decision to start taking Mounjaro - which private clinics will start charging more for come September - came following a series of health concerns linked to her weight. Susan said: 'Two years ago, my blood pressure went through the roof and I was threatened with hospitalisation. 'I was reasonably healthy, but my mobility had been decreasing, and I had very little energy and extensive joint pain.' Doctors recommended she lose weight – and fast – and so the retired sales director started on Wegovy, before switching to a programme with Juniper to receive Mounjaro. WHO IS ELIGIBLE FOR WEIGHT LOSS JABS ON THE NHS? NHS eligibility for weight loss injections has expanded but still lags behind the number who could potentially benefit from taking them. Wegovy, medical name semaglutide, is only available for weight loss through specialist weight management clinics. Patients are typically expected to have tried other weight loss methods before getting a prescription. They may be eligible if their body mass index (BMI) is higher than 30, or higher than 27 if they have a weight-related health condition such as high blood pressure. Mounjaro, known as tirzepatide, is also available from GP practices but currently only to patients with a BMI of 40 or higher (or 37.5 if from a minority ethnic background) plus four weight-related health conditions. The medicines are currently being rationed to the patients most in need. NHS watchdog NICE estimates that more than three million Brits will ultimately be eligible. The GLP-1 injections are prescribed separately by GPs for people with type 2 diabetes, and patients should discuss this with their doctor. Now, Susan is no longer on blood pressure medication, she has no more joint pain, and her thyroid medication dose has been reduced by 25 per cent. The effects of the jabs were noticeable just two weeks into taking them, back in August 2023. Sue said: 'Within a couple of weeks of starting my weight loss journey, my joint pain completely disappeared. 'Cravings for sweet things and large amounts of food also went, and after a month, my blood pressure medication was halved. 'It stopped altogether a few weeks later. 'I had an underactive thyroid and was taking 125mg of Thyroxine, which was then reduced to 100mg. It has been like handing back 16 years of my life Susan Forgie 'I could walk long distances and uphill without getting out of breath, and exercise without tiring. 'I also wanted to eat different foods. 'It's as if my body chemistry has changed and I want lean meat, vegetables and fruit. 'My consumption of alcohol, fatty foods, cream and cheese has dramatically reduced – I simply don't want them.' 7 Susan also recently had a fitness assessment at her local gym, and was stunned to discover her metabolic age puts her at just 59 – 16 years younger than her true age. The 75-year-old says she is 'thrilled' with how her health has improved, having spent decades trying to diet and shift the excess pounds. Susan has spent an estimated £4,600 on the medication over the past 23 months – which she says 'pays for itself' through her reduced food and takeaway spend. She added: 'If somebody had come to me at the beginning and said, 'Pay this money and I will hand back 16 years of your life and improve your health immensely,' I think it would have been a no-brainer. 'My health is the best it has been in many years.' She's been able to stay at 12st 4lbs since August 2024. Susan added: 'I had never been able to do that before! 'I am greatly enjoying the health benefits that have come from losing weight, improved nutrition and increased activity. 'I just celebrated my 75th birthday, but the recent fitness assessment from my gym has calculated a metabolic age of 59 – so I'm thrilled with that. 'It has been like handing back 16 years of my life. 'I'm proof that it's never too late to strive for a healthy weight.'
